Scholarlink

<p>Despite the increasing recognition of metabolic dysfunction-associated fatty liver disease (MAFLD) and Chronic Hepatitis B (CHB), their interplay on liver fibrosis remains insufficiently elucidated. This study aimed to assess liver fibrosis in CHB patients with concurrent MAFLD. This cross-sectional study included 148 patients with a confirmed diagnosis of CHB infection, categorized according to the MAFLD standard criteria into CHB with MAFLD (CHB/+MAFLD) and without MAFLD (CHB/−MAFLD). Demographic, metabolic, and biochemical parameters were analyzed. Fibrosis was assessed non-invasively using vibration-controlled transient elastography (VCTE). A multivariate logistic regression identified independent predictors of significant fibrosis. Among the CHB cohort, 34.5% fulfilled MAFLD criteria. Using FIB-4 &gt; 1.3 for significant fibrosis, the CHB/+MAFLD group exhibited a higher prevalence of significant fibrosis 45.1% vs. 23.7% in the CHB/−MAFLD group, with higher medians in the CHB/+MAFLD group (1.2 vs. 0.8, <i>p</i> &lt; 0.001). Using liver stiffness measurement (LSM), those with MAFLD had a higher prevalence of significant fibrosis (F ≥ 2; 37.3 vs. 16.5%, <i>p</i> 0.005) than in those without MAFLD (medians 6.1 and 5.6&#xa0;kPa, respectively, <i>p</i> 0.03). In multivariate analysis, MAFLD independently increased the odds of significant fibrosis (4.48, 95% CI 1.29–15.6, <i>p</i> 0.019) in CHB patients. The interplay of MAFLD and CHB is associated with worsening liver injury and fibrosis progression. Given the high prevalence of MAFLD and negative impact, metabolic risk assessment should be incorporated into routine CHB care to reduce fibrosis and improve long-term liver outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The coexistence of MAFLD increases fibrosis burden in patients with chronic hepatitis B

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月25日

查看全文
  • Alaa Mohamed Mostafa,
  • Yasser Fouad,
  • Nadia Abdelaaty Abdelkader,
  • Omar Magdy,
  • Nehal Refaat Raouf,
  • Mohammed Eslam

摘要

Despite the increasing recognition of metabolic dysfunction-associated fatty liver disease (MAFLD) and Chronic Hepatitis B (CHB), their interplay on liver fibrosis remains insufficiently elucidated. This study aimed to assess liver fibrosis in CHB patients with concurrent MAFLD. This cross-sectional study included 148 patients with a confirmed diagnosis of CHB infection, categorized according to the MAFLD standard criteria into CHB with MAFLD (CHB/+MAFLD) and without MAFLD (CHB/−MAFLD). Demographic, metabolic, and biochemical parameters were analyzed. Fibrosis was assessed non-invasively using vibration-controlled transient elastography (VCTE). A multivariate logistic regression identified independent predictors of significant fibrosis. Among the CHB cohort, 34.5% fulfilled MAFLD criteria. Using FIB-4 > 1.3 for significant fibrosis, the CHB/+MAFLD group exhibited a higher prevalence of significant fibrosis 45.1% vs. 23.7% in the CHB/−MAFLD group, with higher medians in the CHB/+MAFLD group (1.2 vs. 0.8, p < 0.001). Using liver stiffness measurement (LSM), those with MAFLD had a higher prevalence of significant fibrosis (F ≥ 2; 37.3 vs. 16.5%, p 0.005) than in those without MAFLD (medians 6.1 and 5.6 kPa, respectively, p 0.03). In multivariate analysis, MAFLD independently increased the odds of significant fibrosis (4.48, 95% CI 1.29–15.6, p 0.019) in CHB patients. The interplay of MAFLD and CHB is associated with worsening liver injury and fibrosis progression. Given the high prevalence of MAFLD and negative impact, metabolic risk assessment should be incorporated into routine CHB care to reduce fibrosis and improve long-term liver outcomes.